Search Cancer Clinical Trials
Recruiting
This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.
- Prostate Cancer
- Standard of Care IMRT (Photon)
- Standard of Care Proton Therapy
- Proton Arm 1: Standard Proton Therapy
- Proton Arm 2: Hypofractionated Proton Therapy
N/A
Interventional
Primary Outcome:
- Bowel urgency and bowel frequency Expanded Prostate Cancer Index Composite (EPIC) item scores
Secondary Outcome:
- Grade 2 or higher toxicity for each adverse event assessed by CTCAE
- Grade 2 or higher toxicity for each adverse event assessed by PRO-CTCAE.
- Freedom from biochemical progression using PSA results.
3000
July 5, 2018
- Gender: Male
- Minimum age: 30 Years
- Maximum age: 85 Years
- Healthy volunteers: No
University of Florida
University of Florida
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
NCT03561220
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.